{"id":"agomelatine","rwe":[],"tags":[{"label":"agomelatine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Melatonin receptor type 1A","category":"target"},{"label":"MTNR1A","category":"gene"},{"label":"MTNR1B","category":"gene"},{"label":"HTR2B","category":"gene"},{"label":"N06AX22","category":"atc"},{"label":"Active","category":"status"},{"label":"Major depressive disorder","category":"indication"},{"label":"Les Laboratoires Servier","category":"company"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Hypnotics and Sedatives","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":264.204,"date":"","count":64,"signal":"Amaurosis fugax","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=264)"},{"llr":231.264,"date":"","count":67,"signal":"Ocular discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 67 times (LLR=231)"},{"llr":225.324,"date":"","count":64,"signal":"Urinary tract disorder","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=225)"},{"llr":206.907,"date":"","count":68,"signal":"Haemorrhagic stroke","source":"DrugCentral FAERS","actionTaken":"Reported 68 times (LLR=207)"},{"llr":196.977,"date":"","count":70,"signal":"Head discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 70 times (LLR=197)"},{"llr":159.838,"date":"","count":65,"signal":"Photophobia","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=160)"},{"llr":159.831,"date":"","count":67,"signal":"Generalised oedema","source":"DrugCentral FAERS","actionTaken":"Reported 67 times (LLR=160)"},{"llr":146.353,"date":"","count":73,"signal":"Altered state of consciousness","source":"DrugCentral FAERS","actionTaken":"Reported 73 times (LLR=146)"},{"llr":136.507,"date":"","count":65,"signal":"Blindness","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=137)"},{"llr":133.676,"date":"","count":114,"signal":"Tachycardia","source":"DrugCentral FAERS","actionTaken":"Reported 114 times (LLR=134)"},{"llr":132.865,"date":"","count":65,"signal":"Diplopia","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=133)"},{"llr":124.856,"date":"","count":65,"signal":"Presyncope","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=125)"},{"llr":121.489,"date":"","count":64,"signal":"Eye pain","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=121)"},{"llr":119.495,"date":"","count":67,"signal":"Tinnitus","source":"DrugCentral FAERS","actionTaken":"Reported 67 times (LLR=119)"},{"llr":115.84,"date":"","count":66,"signal":"Haematemesis","source":"DrugCentral FAERS","actionTaken":"Reported 66 times (LLR=116)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Les Laboratoires Servier","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AGOMELATINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:39:44.640645+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Agomelatine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:39:53.198684+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:39:51.665299+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:39:44.667112+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AGOMELATINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:39:52.462705+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Serotonin 2c (5-HT2c) receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:39:53.198626+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL10878/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:39:53.101401+00:00"}},"allNames":"thymanax","offLabel":[],"synonyms":["S20098","S-20098","agomelatine","valdoxan","thymanax"],"timeline":[{"date":"2009-02-19","type":"positive","source":"DrugCentral","milestone":"EMA approval (Les Laboratoires Servier)"}],"aiSummary":"Thymanax (Agomelatine) is a small molecule drug developed by Les Laboratoires Servier, targeting the melatonin receptor type 1A. It is classified as an agomelatine and is approved for the treatment of major depressive disorder. The commercial status of Thymanax is patented, and it is owned by Les Laboratoires Servier. Key safety considerations include its potential effects on liver function and the need for regular monitoring. Thymanax is not FDA-approved.","brandName":"Thymanax","ecosystem":[{"indication":"Major depressive disorder","otherDrugs":[{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"citalopram","slug":"citalopram","company":"Forest Labs"},{"name":"desvenlafaxine","slug":"desvenlafaxine","company":"Wyeth Pharms Inc"}],"globalPrevalence":280000000}],"mechanism":{"target":"Melatonin receptor type 1A","targets":[{"gene":"MTNR1A","source":"DrugCentral","target":"Melatonin receptor type 1A","protein":"Melatonin receptor type 1A"},{"gene":"MTNR1B","source":"DrugCentral","target":"Melatonin receptor","protein":"Melatonin receptor type 1B"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"}],"modality":"Small Molecule","drugClass":"agomelatine","explanation":"","oneSentence":"","technicalDetail":"Agomelatine acts as a selective agonist of the melatonin receptor type 1A (MT1), which is involved in the regulation of the circadian rhythm and mood. By activating MT1 receptors, agomelatine can increase the release of neurotransmitters such as serotonin and dopamine, leading to its antidepressant effects."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Agomelatine","title":"Agomelatine","extract":"Agomelatine, sold under the brand name Thymanax among others, is an atypical antidepressant most commonly used to treat major depressive disorder and generalized anxiety disorder. One review found that it is as effective as other antidepressants with similar discontinuation rates overall but fewer discontinuations due to side effects. Another review also found it was similarly effective to many other antidepressants.","wiki_history":"==History==\nAgomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continued to develop the drug and conduct phase III trials in the European Union.\n\nIn March 2005, Servier submitted agomelatine to the European Medicines Agency (EMA) under the brand names Valdoxan and Thymanax. In September 2007, Servier submitted a new marketing application to the EMA.\n\nIn March 2006, Servier announced it had sold the rights to market agomelatine in the United States to Novartis. It was undergoing several phase III clinical trials in the US, and until October 2011 Novartis listed the drug as scheduled for submission to the FDA no earlier than 2012. However, the development for the US market was discontinued in October 2011, when the results from the last of those trials became available.\n\nIt was authorized for medical use in the European Union in February 2009, and in Australia in August 2010."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/99","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AGOMELATINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AGOMELATINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Agomelatine","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:30:50.730154","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:39:54.981161+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"tryptophan","drugSlug":"tryptophan","fdaApproval":"","relationship":"same-class"},{"drugName":"nomifensine","drugSlug":"nomifensine","fdaApproval":"","relationship":"same-class"},{"drugName":"trazodone","drugSlug":"trazodone","fdaApproval":"1981-12-24","patentExpiry":"Mar 27, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nefazodone","drugSlug":"nefazodone","fdaApproval":"1994-12-22","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"viloxazine","drugSlug":"viloxazine","fdaApproval":"2021-04-02","patentExpiry":"Sep 4, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mirtazapine","drugSlug":"mirtazapine","fdaApproval":"1996-06-14","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bupropion","drugSlug":"bupropion","fdaApproval":"1985-12-30","patentExpiry":"Jun 27, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"venlafaxine","drugSlug":"venlafaxine","fdaApproval":"1993-12-28","genericCount":41,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"milnacipran","drugSlug":"milnacipran","fdaApproval":"2009-01-14","patentExpiry":"Sep 19, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"duloxetine","drugSlug":"duloxetine","fdaApproval":"2004-08-03","patentExpiry":"Apr 13, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"desvenlafaxine","drugSlug":"desvenlafaxine","fdaApproval":"2008-02-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"vilazodone","drugSlug":"vilazodone","fdaApproval":"2011-01-21","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vortioxetine","drugSlug":"vortioxetine","fdaApproval":"2013-09-30","patentExpiry":"Sep 21, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"esketamine","drugSlug":"esketamine","fdaApproval":"2019-05-03","patentExpiry":"Sep 10, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"levomilnacipran","drugSlug":"levomilnacipran","fdaApproval":"2013-07-25","patentExpiry":"May 23, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"brexanolone","drugSlug":"brexanolone","fdaApproval":"2019-03-19","patentExpiry":"Nov 27, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"agomelatine","indications":{"approved":[{"name":"Major depressive disorder","source":"DrugCentral","snomedId":370143000,"regulator":"FDA","usPrevalence":21000000,"globalPrevalence":280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tryptophan","brandName":"tryptophan","genericName":"tryptophan","approvalYear":"","relationship":"same-class"},{"drugId":"nomifensine","brandName":"nomifensine","genericName":"nomifensine","approvalYear":"","relationship":"same-class"},{"drugId":"trazodone","brandName":"trazodone","genericName":"trazodone","approvalYear":"1981","relationship":"same-class"},{"drugId":"nefazodone","brandName":"nefazodone","genericName":"nefazodone","approvalYear":"1994","relationship":"same-class"},{"drugId":"viloxazine","brandName":"viloxazine","genericName":"viloxazine","approvalYear":"2021","relationship":"same-class"},{"drugId":"mirtazapine","brandName":"mirtazapine","genericName":"mirtazapine","approvalYear":"1996","relationship":"same-class"},{"drugId":"bupropion","brandName":"bupropion","genericName":"bupropion","approvalYear":"1985","relationship":"same-class"},{"drugId":"venlafaxine","brandName":"venlafaxine","genericName":"venlafaxine","approvalYear":"1993","relationship":"same-class"},{"drugId":"milnacipran","brandName":"milnacipran","genericName":"milnacipran","approvalYear":"2009","relationship":"same-class"},{"drugId":"duloxetine","brandName":"duloxetine","genericName":"duloxetine","approvalYear":"2004","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07011693","phase":"PHASE4","title":"Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)","status":"NOT_YET_RECRUITING","sponsor":"Xinyu Zhou","startDate":"2025-06-20","conditions":["Major Depressive Disorder (MDD)"],"enrollment":400,"completionDate":"2027-12"},{"nctId":"NCT03852160","phase":"PHASE3","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen-Cilag International NV","startDate":"2019-12-01","conditions":["Depressive Disorder, Treatment-Resistant"],"enrollment":0,"completionDate":"2021-07-25"},{"nctId":"NCT01108393","phase":"PHASE2","title":"Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2010-05","conditions":["Obsessive Compulsive Disorder"],"enrollment":74,"completionDate":"2013-04"},{"nctId":"NCT04589143","phase":"PHASE4","title":"A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine","status":"COMPLETED","sponsor":"Central South University","startDate":"2020-10-01","conditions":["Major Depressive Disorder"],"enrollment":137,"completionDate":"2023-01-30"},{"nctId":"NCT06120543","phase":"","title":"CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in Adult Patients With Depression","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2023-10-31","conditions":["Polymorphism, Genetic","Depression","CYP1A2 Polymorphism","CYP2C9 Polymorphism","Polymerase Chain Reaction","Plasma Concentration"],"enrollment":50,"completionDate":"2025-03-31"},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":["Major Depressive Disorder","Magnetic Resonance Imaging","Electroconvulsive Therapy"],"enrollment":180,"completionDate":"2026-01-01"},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":["Major Depressive Disorder"],"enrollment":73336,"completionDate":"2023-07-01"},{"nctId":"NCT05646264","phase":"PHASE4","title":"A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2023-01-01","conditions":["Schizophrenia","Negative Symptoms in Schizophrenia"],"enrollment":220,"completionDate":"2023-08-01"},{"nctId":"NCT05426304","phase":"PHASE4","title":"Prophylactic Effects of Agomelatine for Poststroke Depression","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-10-01","conditions":["Depression","Acute Ischemic Stroke"],"enrollment":420,"completionDate":"2024-05-31"},{"nctId":"NCT01531309","phase":"PHASE1","title":"Pharmacokinetics of AGO178 in Participants With Liver Impairment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02-08","conditions":["Hepatic Impairment"],"enrollment":32,"completionDate":"2011-09-02"},{"nctId":"NCT01156415","phase":"PHASE3","title":"Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":["Major Depressive Disorder"],"enrollment":837,"completionDate":"2011-10"},{"nctId":"NCT01110902","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05","conditions":["Major Depressive Disorder"],"enrollment":589,"completionDate":"2011-06"},{"nctId":"NCT00411242","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":["Major Depressive Disorder (MDD)"],"enrollment":503,"completionDate":""},{"nctId":"NCT00411099","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":["Major Depressive Disorder"],"enrollment":508,"completionDate":""},{"nctId":"NCT01110889","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05","conditions":["Major Depressive Disorder"],"enrollment":582,"completionDate":""},{"nctId":"NCT00467402","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":["Major Depressive Disorder"],"enrollment":644,"completionDate":""},{"nctId":"NCT00463242","phase":"PHASE3","title":"A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":["Major Depressive Disorder"],"enrollment":501,"completionDate":""},{"nctId":"NCT04181567","phase":"PHASE4","title":"Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients","status":"COMPLETED","sponsor":"Kaohsiung Kai-Suan Psychiatric Hospital","startDate":"2014-03-03","conditions":["Major Depressive Disorder"],"enrollment":97,"completionDate":"2019-11-22"},{"nctId":"NCT03977441","phase":"PHASE4","title":"the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2019-07","conditions":["Parkinson Disease","Depression","Sleep Disorders","Circadian Rhythm Disorders"],"enrollment":240,"completionDate":"2020-12"},{"nctId":"NCT03193112","phase":"","title":"Melatonin Decreases Eye Pressure in Normotensive Patients","status":"COMPLETED","sponsor":"Kahramanmaras Sutcu Imam University","startDate":"2017-06-16","conditions":["Depressive Disorder"],"enrollment":20,"completionDate":"2018-06-15"},{"nctId":"NCT01822418","phase":"PHASE4","title":"Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2013-01","conditions":["Schizophrenia","Schizoaffective Disorder","Delusional Disorder"],"enrollment":27,"completionDate":"2015-12"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":["Major Depression Disorder"],"enrollment":132,"completionDate":"2016-06"},{"nctId":"NCT01731899","phase":"","title":"Agomelatine in Depressed Patients With Fibromyalgia","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2010-06","conditions":["Major Depression","Fibromyalgia"],"enrollment":27,"completionDate":"2012-11"},{"nctId":"NCT01488071","phase":"PHASE3","title":"A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-01","conditions":["Major Depressive Disorder"],"enrollment":495,"completionDate":""},{"nctId":"NCT01483053","phase":"PHASE4","title":"Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)","status":"UNKNOWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2014-01","conditions":["Major Depressive Disorder (MDD)"],"enrollment":40,"completionDate":"2015-02"},{"nctId":"NCT00451490","phase":"NA","title":"The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder","status":"WITHDRAWN","sponsor":"National Taiwan University Hospital","startDate":"2006-10","conditions":["Depressive Disorder, Major"],"enrollment":24,"completionDate":"2007-12"}],"_emaApprovals":[{"date":"2009-02-19","status":"Authorised","company":"Les Laboratoires Servier"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"013126","UNII":"137R1N49AD","CHEBI":"CHEBI:134990","INN_ID":"7392","UMLSCUI":"C0971637","chemblId":"CHEMBL10878","ChEMBL_ID":"CHEMBL10878","KEGG_DRUG":"D02578","DRUGBANK_ID":"DB06594","PDB_CHEM_ID":"AWY","PUBCHEM_CID":"82148","SNOMEDCT_US":"698012009","IUPHAR_LIGAND_ID":"198","MESH_SUPPLEMENTAL_RECORD_UI":"C084711"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Les Laboratoires Servier","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","fractionUnbound":"0.073%"},"publicationCount":1063,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N06AX22","allCodes":["N06AX22"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Les Laboratoires Servier","companyId":"les-laboratoires-servier","modality":"Small molecule","firstApprovalDate":"2009","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:39:54.981161+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}